Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, Pisconti S, Petrelli F, Vacca A, Lorusso V. Gnoni A, et al. Among authors: scartozzi m. Crit Rev Oncol Hematol. 2015 Jul;95(1):46-61. doi: 10.1016/j.critrevonc.2015.01.008. Epub 2015 Jan 20. Crit Rev Oncol Hematol. 2015. PMID: 25656744 Review.
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, Crinò L, De Marinis F, Di Pietro FA, Grossi F, Innocenzi D, Micali G, Piantedosi FV, Scartozzi M. Gridelli C, et al. Among authors: scartozzi m. Crit Rev Oncol Hematol. 2008 May;66(2):155-62. doi: 10.1016/j.critrevonc.2007.10.004. Epub 2007 Dec 20. Crit Rev Oncol Hematol. 2008. PMID: 18083041
Pancreatic cancer: progress in cancer therapy.
Pierantoni C, Pagliacci A, Scartozzi M, Berardi R, Bianconi M, Cascinu S. Pierantoni C, et al. Among authors: scartozzi m. Crit Rev Oncol Hematol. 2008 Jul;67(1):27-38. doi: 10.1016/j.critrevonc.2008.01.009. Epub 2008 Mar 19. Crit Rev Oncol Hematol. 2008. PMID: 18356073 Review.
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. Loupakis F, et al. Among authors: scartozzi m. J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27. J Clin Oncol. 2009. PMID: 19398573
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G. Santini D, et al. Among authors: scartozzi m. Ann Oncol. 2012 Sep;23(9):2313-2318. doi: 10.1093/annonc/mdr623. Epub 2012 Mar 5. Ann Oncol. 2012. PMID: 22396447 Free article. Clinical Trial.
376 results